Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
INMD · against 483 other Healthcare companies of similar size
Ranked #14 of 484 · scores higher than 96% of peers
Bars: peers in each 10-point band of the valuation score53 peers with a valuation score of 90–100, including INMD · Click a bar to see the companies
Mainly thanks to its EBITDA yield, free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | INMD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 471 reported | 8.6% | 1.1% | 93% | 30% | |
| EBITDA yieldHigher is better · 490 reported | 21.2% | 4.1% | 96% | 50% | |
| Free cash flow yieldHigher is better · 199 reported | 10.2% | -2.7% | 93% | 20% | |
| Book yieldHigher is better · 480 reported | 75.9% | 43.1% | 78% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 1 | 57.0B INR (≈$684M) | 99 | 40 | |
| 14 | 3.8B HKD (≈$486M) | 96 | 56 | |
| 14 | 72.6B JPY (≈$494M) | 96 | 58 | |
| 14 | 595M USD | 96 | 97 | |
| 14 | 433M USD | 96 | 81 | |
| 14 | 810M USD | 96 | 69 | |
| 14 | 578M USD | 96 | 73 | |
| 14 | 1.2B USD | 96 | 75 | |
| 21 | 6.6B HKD (≈$840M) | 95 | 71 | |
| 21 | 3.4B CNY (≈$478M) | 95 | 77 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score